EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Cartesian Therapeutics, Inc. (RNAC) EBITDA Margin data is not available.
| Income Statement Financials | |
$0.95M |
|
$-89.95M |
|
-- |
|
$0.95M |
|
$79.59M |
|
$-78.64M |
|
$-23.13M |
|
$-101.77M |
|
$-101.77M |
|
$-92.58M |
|
$-92.58M |
|
$-92.58M |
|
$-92.58M |
|
$-78.64M |
|
$-78.03M |
|
25.97M |
|
25.97M |
|
$-3.47 |
|
$-3.46 |
|
| Balance Sheet Financials | |
$129.28M |
|
$12.19M |
|
$167.13M |
|
$296.41M |
|
$14.94M |
|
-- |
|
$407.71M |
|
$422.65M |
|
$-126.24M |
|
$-174.40M |
|
$-126.24M |
|
26.01M |
|
| Cash Flow Statement Financials | |
$-73.94M |
|
$-5.45M |
|
$-8.05M |
|
$214.28M |
|
$126.87M |
|
$-87.41M |
|
$10.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-8304.01% |
|
-8304.01% |
|
|
EBITDA Margin |
-- |
-10746.46% |
|
-9498.21% |
|
$-79.39M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.85 |
|
105.97 |
|
73.33% |
|
53.08% |
|
-31.23% |
|
73.33% |
|
$-4.85 |
|
$-3.06 |
|
$-2.85 |
|